Featured Research

from universities, journals, and other organizations

Race, Family History Or Baseline PSA: Which Best Predicts Prostate Cancer Risk?

Date:
May 15, 2008
Source:
American Urological Association
Summary:
African-American men with family histories of prostate cancer could benefit from a baseline prostate-specific antigen (PSA) reading to determine their probability of developing the disease.

African-American men with family histories of prostate cancer could benefit from a baseline prostate-specific antigen (PSA) reading to determine their probability of developing the disease. Researchers from Northwestern University in Chicago say this new perspective on testing could lead to highly individualized screening protocols based on a man’s baseline level and how it relates to established age-specific medians.

According to new data presented recently during the Annual Scientific Meeting of the American Urological Association (AUA) in Orlando, African-American men with known prostate cancer risk factors with baseline levels higher than the age-specific median are more likely to develop the disease in their lifetimes than the general population. However, African-American men with a family history were unlikely to develop prostate cancer if their baseline PSA level was below the age-specific median.

The effect of the baseline PSA level on future prostate cancer risk was so robust that the correlation held true even for men with other significant risk factors.

Using a study cohort drawn from a longitudinal screening study enrolling more than 26,000 volunteers between 1991 and 2001, researchers analyzed a group of 329 African-American men with a family history of prostate cancer. The volunteers were divided into three groups by ages: 40s, 50s and 60+ with a mean follow-up time of 19.5, 71 and 81 months, respectively. None of the men in their 40s or 50s with both risk factors and a baseline PSA below the median were diagnosed with prostate cancer.

Eight percent of men in their 40s with both risk factors and a PSA above the median were diagnosed, as were 16 percent of men in their 50s. Twice as many men in their 60s with both risk factors and a baseline PSA above the median were diagnosed with prostate cancer.


Story Source:

The above story is based on materials provided by American Urological Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mondo DM, Roehl KA, Loeb S, Gashti SN, Griffin CR, Smith ND et al: Which is the most important risk factor for prostate cancer: race, family history, or baseline PSA level? J Urol, suppl., 2008; 179: 148, abstract 417. [link]

Cite This Page:

American Urological Association. "Race, Family History Or Baseline PSA: Which Best Predicts Prostate Cancer Risk?." ScienceDaily. ScienceDaily, 15 May 2008. <www.sciencedaily.com/releases/2008/05/080515072912.htm>.
American Urological Association. (2008, May 15). Race, Family History Or Baseline PSA: Which Best Predicts Prostate Cancer Risk?. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/05/080515072912.htm
American Urological Association. "Race, Family History Or Baseline PSA: Which Best Predicts Prostate Cancer Risk?." ScienceDaily. www.sciencedaily.com/releases/2008/05/080515072912.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins